Showing 1–3 of 3 companies
With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a rob
CMIC’s goal is to provide our pharmaceutical industry customers with a knowledgeable and trustworthy business partner … one who can formulate, process, test, and manufacture your oral dosage forms
Matt Hoffman, Editor, NeurologyLive, has covered medical news for MJH Associates, NeurologyLive’s parent company, since 2017, and previously wrote for its sister publication, MD Mag.